{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-018211","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.756230+00:00","generated_at":"2026-05-15T11:47:55.356295+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1","bullets":["Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.","Post hoc LOCF analysis showed significant BMI reductions: POMC/PCSK1 -5.5% (p=0.0010), SRC1 -6.2% (p<0.0001) vs placebo.","Completer analysis: placebo-adjusted BMI -9.7% (POMC/PCSK1, n=41, p=0.0002) and -8.0% (SRC1, n=29, p=0.0158).","Safety profile consistent with prior studies; no new signals. Common AEs: skin hyperpigmentation, injection-site reactions.","Rhythm to evaluate next-gen MC4R agonists bivamelagon and RM-718 for SRC1 and POMC; continuing DAYBREAK exploratory work."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-018211","json":"https://secwatch.observer/filing/0001628280-26-018211.json","markdown":"https://secwatch.observer/filing/0001628280-26-018211.md","text":"https://secwatch.observer/filing/0001628280-26-018211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/0001628280-26-018211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/rytm-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:47:55.356295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}